Failed growth hormone trial shrinks Peninsula drug company's stock more than 80%

The company lost more than 80 percent of its value by mid-day Friday after its attempt to tap a $3 billion growth hormone market failed a late-stage clinical trial.
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news